Kidney shield after bypass? drug trial halted early
NCT ID NCT05524051
First seen Nov 19, 2025 · Last updated May 21, 2026 · Updated 28 times
Summary
This study tested a drug called TIN816 to see if it could prevent acute kidney injury in adults after heart surgery. About 102 people were planned to take part, but the study was stopped early. The goal was to measure kidney function using a blood test called serum creatinine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY FOLLOWING CARDIAC SURGERY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke Univ Medical Center
Durham, North Carolina, 27710, United States
-
Mayo Clinic Phoenix
Phoenix, Arizona, 85054, United States
-
Novartis Investigative Site
CABA, Buenos Aires, C1118AAT, Argentina
-
Novartis Investigative Site
Buenos Aires, C1428DCO, Argentina
-
Novartis Investigative Site
CABA, C1181ACH, Argentina
-
Novartis Investigative Site
Genk, Limburg, 3600, Belgium
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Salvador, Estado de Bahia, 40323-010, Brazil
-
Novartis Investigative Site
São Paulo, São Paulo, 05403 000, Brazil
-
Novartis Investigative Site
Montreal, Quebec, H1T 1C8, Canada
-
Novartis Investigative Site
Montreal, Quebec, H2X 0A9, Canada
-
Novartis Investigative Site
Montreal, Quebec, H4J 1C5, Canada
-
Novartis Investigative Site
Québec, Quebec, GIV 4G5, Canada
-
Novartis Investigative Site
Ostrava, Poruba, 708 52, Czechia
-
Novartis Investigative Site
Tartu, 50406, Estonia
-
Novartis Investigative Site
Nantes, 44093, France
-
Novartis Investigative Site
Neuilly-sur-Seine, 92200, France
-
Novartis Investigative Site
Paris, 75013, France
-
Novartis Investigative Site
Poitiers, 86021, France
-
Novartis Investigative Site
Rennes, 35033, France
-
Novartis Investigative Site
Regensburg, Bavaria, 93053, Germany
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Leipzig, Saxony, 04289, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Pécs, Baranya, 7623, Hungary
-
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, 4032, Hungary
-
Novartis Investigative Site
Budapest, H 1096, Hungary
-
Novartis Investigative Site
Budapest, H-1083, Hungary
-
Novartis Investigative Site
Ahmedabad, Gujarat, 380054, India
-
Novartis Investigative Site
Lucknow, Uttar Pradesh, 226003, India
-
Novartis Investigative Site
Vilnius, LT-08406, Lithuania
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
Badalona, Barcelona, 08916, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08907, Spain
-
Novartis Investigative Site
Madrid, 28006, Spain
-
Novartis Investigative Site
Taipei, 10002, Taiwan
Conditions
Explore the condition pages connected to this study.